Back

Transcranial direct current stimulation-augmented cognitive training for post-COVID-19 cognition: A phase IIb randomized controlled trial

Trujillo Llano, C.; Fromm, A. E.; Lingemann, L.; Grittner, U.; Meinzer, M. F.; Fleischmann, R.; Brakemeier, E.-L.; Antonenko, D. F.; Floeel, A.

2026-05-14 neurology
10.64898/2026.05.11.26352906 medRxiv
Show abstract

BackgroundCognitive dysfunction is a prevalent and debilitating symptom of post-COVID-19 condition with limited evidence-based interventions. Here, we assessed the efficacy of cognitive training (CT) alone and combined with transcranial direct current stimulation (tDCS) for cognitive enhancement in post-COVID-19 patients. MethodsNeuromod-COV was a phase IIb, prospective, randomized, open-label, blinded-endpoint trial conducted at University Medicine Greifswald, Germany. The tDCS intervention was evaluated through a double-blind, sham-controlled design. Adults aged 18-60 with confirmed SARS-CoV-2 infection [≥] 6 weeks prior and post-infection cognitive complaints were eligible. Participants were randomly assigned (1:1:1) to CT with active tDCS (CT+AtDCS), CT with sham tDCS (CT+StDCS), or progressive muscle relaxation (PMR, non-cognitive control intervention) with sham tDCS. Intervention consisted of nine 20-minute sessions over three weeks of CT (letter updating task) or PMR with 2 mA tDCS (active/sham) applied over the left dorsolateral prefrontal cortex. The primary outcome was untrained working memory (WM; measured by N-back task accuracy) comparing CT with PMR at post-intervention. Secondary outcomes included trained and untrained WM, visuospatial memory, and self-report measures at post-intervention and 1-month follow-up comparing CT vs. PMR and CT+AtDCS vs. CT+StDCS. The trial was registered at ClinicalTrials.gov (NCT04944147). ResultsBetween October 1, 2021, and August 7, 2024, 60 participants were randomized (76.7% female) to CT+AtDCS (n = 20), CT+StDCS (n = 20), or PMR (n = 20). CT did not improve untrained WM at post-intervention compared with PMR (primary outcome: {beta} = 1.59, 95% CI - 1.30 to 4.48, p = 0.278; 1-back: {beta} = 2.52, 95% CI -1.27 to 6.31, p = 0.191; 2-back: {beta} = 0.66, 95% CI -3.12 to 4.44, p = 0.732). However, CT+AtDCS enhanced untrained WM at post-intervention and follow-up, and visuospatial memory at post-intervention compared with CT+StDCS (secondary outcomes). No intervention improved self-report outcomes. No serious adverse events occurred and incidence rate ratios were similar between groups. ConclusionCT alone did not improve untrained WM performance. However, CT with tDCS enhanced untrained WM and visuospatial memory, suggesting potential benefits of combined neuromodulation approaches for cognitive enhancement in post-COVID-19 patients.

Matching journals

The top 7 journals account for 50% of the predicted probability mass.

1
Neuroscience & Biobehavioral Reviews
43 papers in training set
Top 0.1%
17.5%
2
Brain Stimulation
112 papers in training set
Top 0.3%
12.5%
3
Brain, Behavior, and Immunity
105 papers in training set
Top 0.2%
8.4%
4
Journal of Neurology, Neurosurgery & Psychiatry
29 papers in training set
Top 0.2%
4.8%
5
Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
62 papers in training set
Top 0.4%
4.0%
6
Scientific Reports
3102 papers in training set
Top 42%
2.9%
7
Alzheimer's & Dementia
143 papers in training set
Top 2%
2.7%
50% of probability mass above
8
BMC Medicine
163 papers in training set
Top 2%
2.7%
9
Molecular Psychiatry
242 papers in training set
Top 1%
2.6%
10
PLOS ONE
4510 papers in training set
Top 46%
2.4%
11
Journal of Translational Medicine
46 papers in training set
Top 0.7%
1.8%
12
eBioMedicine
130 papers in training set
Top 1%
1.7%
13
Nature Communications
4913 papers in training set
Top 53%
1.7%
14
Frontiers in Psychiatry
83 papers in training set
Top 2%
1.3%
15
PLOS Medicine
98 papers in training set
Top 3%
1.2%
16
NeuroImage: Clinical
132 papers in training set
Top 3%
0.9%
17
npj Digital Medicine
97 papers in training set
Top 3%
0.9%
18
Neurotherapeutics
11 papers in training set
Top 0.5%
0.8%
19
Journal of Affective Disorders
81 papers in training set
Top 2%
0.7%
20
Neuro-Oncology
30 papers in training set
Top 0.7%
0.7%
21
eLife
5422 papers in training set
Top 58%
0.7%
22
Cerebral Cortex
357 papers in training set
Top 2%
0.7%
23
Frontiers in Aging Neuroscience
67 papers in training set
Top 3%
0.7%
24
Biological Psychiatry
119 papers in training set
Top 3%
0.7%
25
Cell Reports Medicine
140 papers in training set
Top 9%
0.7%
26
JAMA Network Open
127 papers in training set
Top 5%
0.7%
27
Med
38 papers in training set
Top 1%
0.6%
28
Schizophrenia
19 papers in training set
Top 0.4%
0.6%
29
Neurology
44 papers in training set
Top 2%
0.6%
30
Human Brain Mapping
295 papers in training set
Top 5%
0.6%